Literature DB >> 22424726

Headaches related to psychoactive substance use.

Yeşim Yetimalar Beckmann1, Mustafa Seçkin, Ali İlhan Manavgat, Nabi Zorlu.   

Abstract

AIM: To investigate a possible association between headache and psychoactive substance use.
METHODS: 1055 psychoactive substance abusers were consecutively admitted. All patients filled out a detailed headache questionnaire and 1015 patients were included.
RESULTS: Twenty seven percent of patients reported having headache. Eighteen percent of patients reported having headache attributed to a substance or its withdrawal and 1.4% had unclassified headache. The most commonly used substances were cannabis (80.5%), alcohol (74.6%), methylamphetamine (18.7%), benzodiazepine (10.4%), volatile solvent (5.8%), cocaine (4.4%), heroin (2.1%), opioids (0.5%), and other substances (1.7%). Fifteen patients reported that onset of headache occurred prior to onset of substance use, while 94.5% had headaches occurred after substance abuse. A higher incidence of headache was found in the benzodiazepine, methylamphetamine, cocaine, heroin, volatile solvent abusers. Seventy-eight percent of headache patients have never sought help from a physician despite the severity and frequency of headache.
CONCLUSIONS: In our study, the prevalence of headache among all psychoactive substance abusers was 26.9%. Although this is one-group study without any comparison with non-addict population and associational data must be interpreted with caution, the results of this study indicate a possible relationship may exist between headache and substance use since 94.5% of substance users described headaches after the onset of substance use. The younger start and the longer duration of cannabis use caused the higher incidence of headache, but this correlation was not observed in other substance use. Migraine was far more prevalent in the abusers than in previously reported community populations.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22424726     DOI: 10.1016/j.clineuro.2012.02.041

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Application of density estimation algorithms in analyzing co-morbidities of migraine.

Authors:  Meng-Han Yang; Fu-Yi Yang; Yen-Jen Oyang
Journal:  Netw Model Anal Health Inform Bioinform       Date:  2013-02-12

2.  Experts' opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta.

Authors:  Aynur Özge; Ishaq Abu-Arafeh; Amy A Gelfand; Peter James Goadsby; Jean Christophe Cuvellier; Massimiliano Valeriani; Alexey Sergeev; Karen Barlow; Derya Uludüz; Osman Özgür Yalın; Noemi Faedda; Richard B Lipton; Alan Rapoport; Vincenzo Guidetti
Journal:  J Headache Pain       Date:  2017-11-29       Impact factor: 7.277

Review 3.  Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.

Authors:  Yara Mouhamed; Andrey Vishnyakov; Bessi Qorri; Manpreet Sambi; Sm Signy Frank; Catherine Nowierski; Anmol Lamba; Umrao Bhatti; Myron R Szewczuk
Journal:  Drug Healthc Patient Saf       Date:  2018-06-11

Review 4.  Lifestyle Modifications to Help Prevent Headache at a Developmental Age.

Authors:  Umberto Raucci; Alessandra Boni; Melania Evangelisti; Nicoletta Della Vecchia; Margherita Velardi; Fabiana Ursitti; Gianluca Terrin; Giovanni Di Nardo; Antonino Reale; Alberto Villani; Pasquale Parisi
Journal:  Front Neurol       Date:  2021-02-02       Impact factor: 4.003

5.  Heroin-induced headache in female heroin addicts.

Authors:  Li Li; Shengyuan Yu
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

Review 6.  Chronic traumatic encephalopathy neuropathology might not be inexorably progressive or unique to repetitive neurotrauma.

Authors:  Grant L Iverson; Andrew J Gardner; Sandy R Shultz; Gary S Solomon; Paul McCrory; Ross Zafonte; George Perry; Lili-Naz Hazrati; C Dirk Keene; Rudolph J Castellani
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.